alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

29,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 151–175 of 547 studies scoring ≥ 70 out of 100 · free to read (page 7 of 22) · 29,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 15,255 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial

✓ Peer-reviewed alzhub usefulness score 76 out of 100. The Lancet. Neurology 2008-07-07

Observational epidemiological studies have shown a positive association between hypertension and risk of incident dementia; however, the effects of antihypertensive therapy on cognitive function in controlled trials have been conflicting, and meta-analyses of the trials have not provided clear evidence of whether antihypertensive treatment reduces dementia incidence. 5 key findings →

Design: meta-analysis Participants: 1,687 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Acta neuropathologica 2020-07-27

The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease (AD). 4 key findings →

Design: longitudinal study Participants: 115 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Molecular psychiatry 2020-10-26

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease (AD), their broad implementation in clinical and trial settings are restricted by high cost and limited accessibility. 3 key findings →

Design: longitudinal study Participants: 1,000 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis

✓ Peer-reviewed alzhub usefulness score 76 out of 100. JAMA neurology 2025-03-03

Mounting evidence in adults without AD indicates that females exhibit higher tau deposition than age-matched males, particularly in the setting of elevated β-amyloid (Aβ), but the evidence for sex differences in tau accumulation rates is inconclusive. 5 key findings →

Design: meta-analysis Participants: 1,376 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial

✓ Peer-reviewed alzhub usefulness score 76 out of 100. BMJ (Clinical research ed.) 2006-11-17

Occupational therapy improved patients' daily functioning and reduced the burden on the care giver, despite the patients' limited learning ability. 2 key findings →

Design: randomized controlled trial Participants: 135 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Delirium With Long-term Cognitive Decline: A Meta-analysis

✓ Peer-reviewed alzhub usefulness score 76 out of 100. JAMA neurology 2020-11-01

Of 1583 articles, data subjected from the 24 studies (including 3562 patients who experienced delirium and 6987 controls who did not) were included in a random-effects meta-analysis for pooled effect estimates and random-effects meta-regressions to identify sources of study variance. 3 key findings →

Design: systematic review Participants: 3,562 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Nature medicine 2022-11-10

A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. 3 key findings →

Participants: 1,325 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Alzheimer's research & therapy 2023-02-28

Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). 4 key findings →

Participants: 182 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA neurology 2017-05-01

Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman ρ = 0.59, P Conclusions and relevance Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. 3 key findings →

Design: case-control study Participants: 197 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA neurology 2021-12-01

This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD. 5 key findings →

Design: cross-sectional Participants: 300 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA neurology 2021-04-01

Exclusion criteria included any significant neurologic disorder other than suspected AD; presence of infection, infarction, or multiple lacunes as detected by magnetic resonance imaging; and any significant systemic condition that could lead to difficulty complying with the protocol. 3 key findings →

Design: cohort study Participants: 1,113 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA 2017-04-01

An increasing number of midlife vascular risk factors was significantly associated with elevated amyloid SUVR; this association was not significant for late-life risk factors. 5 key findings →

Design: cohort study Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Neurology 2014-06-13

Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research. 2 key findings →

Participants: 3,275 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Archives of internal medicine 2002-10-01

Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. 2 key findings →

Participants: 1,485 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 75 out of 100. JAMA 2003-10-01

Exercise training for patients with Alzheimer disease combined with teaching caregivers how to manage behavioral problems may help decrease the frailty and behavioral impairment that are often prevalent in patients with Alzheimer disease. 1 key finding →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Physical Activity, Cognition, and Brain Outcomes: A Review of the 2018 Physical Activity Guidelines

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Medicine and science in sports and exercise 2019-06-01

There is moderate-to-strong support that PA benefits cognitive functioning during early and late periods of the life span and in certain populations characterized by cognitive deficits. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data

✓ Peer-reviewed alzhub usefulness score 75 out of 100. The Lancet. Global health 2019-05-01

The overall weighted PAF for potentially modifiable risk factors for dementia was 39·5% (95% CI 37·5-41·6) in China (n=2162 participants), 41·2% (39·1-43·4) in India (n=2004), and 55·8% (54·9-56·7) in our Latin American sample (n=12 865). 2 key findings →

Design: meta-analysis Participants: 2,162 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed